Key Findings from the Genomic Landscape for ALS
This comprehensive report reveals research-driven insights from Genomenon’s comprehensive Genomic Landscape for Amyotrophic Lateral Sclerosis (ALS), and their implications for drug development and discovery within Pharma.
KEY FINDINGS INCLUDE
- Expansion of the list of causative genes and variants for ALS
- Uncovered trends in Age at Onset and Rate of Progression
- New data on the prevalence of gene mutations in ALS
- Validation of the novel utility of the Genomic Landscape for ALS
The content as presented in the report is for informational purposes only, and is not intended to be a substitute for professional medical advice. Moreover, this data is subject to periodic updates as new information is published and assimilated.
DOWNLOAD THE FREE REPORT
Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.
Genomenon Genomic Landscapes provide the complete picture of a disease or pathway with a unique 2-pronged approach
Genomenon’s Computational Intelligence organizes and indexes all medical evidence and makes it easily searchable
Genomenon’s Experts assess the variants for clinical effect, score for pathogenicity, and review to ensure data quality
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.